{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T01:13:22Z","timestamp":1790558002521,"version":"4.1.0"},"reference-count":35,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Objectives: The study aims to evaluate adherence to Romosozumab treatment in osteoporotic patients after surgical fracture fixation and compare side effects with non-fractured controls on the same therapy. Methods: This retrospective case\u2013control study was conducted at the Orthopaedic Department of Policlinico Universitario di Roma \u201cTor Vergata\u201d, following the principles of the Declaration of Helsinki. It included postmenopausal women aged over 60, with the case group receiving Romosozumab after fracture fixation, and the control group consisting of women on Romosozumab therapy without fracture fixation. Exclusion criteria included psychiatric conditions, contraindications to Romosozumab, high-energy trauma, or other bone metabolism disorders. Data on fractures, surgeries, FRAX (Fracture Risk Assessment Tool) scores, BMD (Bone Mineral Densit) values, and follow-up details were collected. Side effects, including nasopharyngitis and severe events like hypocalcemia, stroke, and myocardial infarction, were recorded. Adherence was assessed via pharmacy records and patient interviews during routine clinical follow-up visits. Statistical analysis was performed using descriptive statistics, t-tests, and chi-square tests. Results: The study included 25 patients, with 12 in the surgical group and 13 in the conservative treatment group. The surgical group had a mean age of 67.3 years and a follow-up of 374 days, while the conservative group had a mean age of 76.4 years and a follow-up of 287 days. The surgical group underwent various fracture treatments, including femoral, humeral, and distal radius fractures, while the conservative group was treated with immobilization. There were no significant differences in FRAX scores or BMD values between the two groups. Vitamin D levels increased significantly in both groups after supplementation, but parathyroid hormone levels showed no difference. No new fractures occurred, and surgical patients had no delayed union or nonunion, though two had superficial wound infections. Conclusions: Both groups adhered well to Romosozumab therapy, with no severe side effects; minor side effects included myalgia in the surgical group and shoulder arthralgia in the conservative group. Romosozumab is well-tolerated and adherent in osteoporotic patients after osteosynthesis surgery, with adverse events similar to non-fractured individuals. While the study design is appropriate, multicenter trials would improve the sample size and allow for subgroup analysis based on fracture type and demographics.<\/jats:p>","DOI":"10.3390\/diseases13050148","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T04:21:23Z","timestamp":1747023683000},"page":"148","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Examining Romosozumab Adherence and Side Effects in Osteoporotic Patients After Surgical Fracture Fixation: A Comparative, Descriptive, and Hypothesis-Generating Study with Non-Fractured Controls"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-6785","authenticated-orcid":false,"given":"Amarildo","family":"Smakaj","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences and Translational Medicine, \u201cTor Vergata\u201d University of Rome, 00133 Rome, Italy"},{"name":"Department of Orthopaedics and Traumatology, \u201cPoliclinico Tor Vergata\u201d Foundation, 00133 Rome, Italy"},{"name":"Department of Biomedicine and Prevention, \u201cTor Vergata\u201d University of Rome, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0330-2189","authenticated-orcid":false,"given":"Umberto","family":"Tarantino","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Translational Medicine, \u201cTor Vergata\u201d University of Rome, 00133 Rome, Italy"},{"name":"Dipartimento di Scienze Chirurgiche, Universit\u00e0 Cattolica Nostra Signora del Buon Consiglio, 1000 Tirana, Albania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Iundusi","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Translational Medicine, \u201cTor Vergata\u201d University of Rome, 00133 Rome, Italy"},{"name":"Department of Orthopaedics and Traumatology, \u201cPoliclinico Tor Vergata\u201d Foundation, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Chiavoghilefu","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Translational Medicine, \u201cTor Vergata\u201d University of Rome, 00133 Rome, Italy"},{"name":"Department of Orthopaedics and Traumatology, \u201cPoliclinico Tor Vergata\u201d Foundation, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Abbondante","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Translational Medicine, \u201cTor Vergata\u201d University of Rome, 00133 Rome, Italy"},{"name":"Department of Orthopaedics and Traumatology, \u201cPoliclinico Tor Vergata\u201d Foundation, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Salvati","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Translational Medicine, \u201cTor Vergata\u201d University of Rome, 00133 Rome, Italy"},{"name":"Department of Orthopaedics and Traumatology, \u201cPoliclinico Tor Vergata\u201d Foundation, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3205-4030","authenticated-orcid":false,"given":"Chiara","family":"Greggi","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Translational Medicine, \u201cTor Vergata\u201d University of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gasbarra","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Translational Medicine, \u201cTor Vergata\u201d University of Rome, 00133 Rome, Italy"},{"name":"Department of Orthopaedics and Traumatology, \u201cPoliclinico Tor Vergata\u201d Foundation, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the European Union: Medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"8","author":"Hernlund","year":"2013","journal-title":"Arch. Osteoporos."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11657-020-0706-y","article-title":"Fragility fractures in Europe: Burden, management and opportunities","volume":"15","author":"Karlsson","year":"2020","journal-title":"Arch. Osteoporos."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","article-title":"SCOPE 2021: A new scorecard for osteoporosis in Europe","volume":"16","author":"Kanis","year":"2021","journal-title":"Arch. Osteoporos."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00198-018-4732-1","article-title":"Risk of subsequent fracture after prior fracture among older women","volume":"30","author":"Balasubramanian","year":"2019","journal-title":"Osteoporos. Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00198-010-1178-5","article-title":"Risk of subsequent fracture and mortality within 5 years after a non-vertebral fracture","volume":"21","author":"Huntjens","year":"2010","journal-title":"Osteoporos. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/BOT.0b013e3181f9b389","article-title":"A comprehensive approach to fragility fractures","volume":"25","author":"Rebolledo","year":"2011","journal-title":"J. Orthop. Trauma."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00198-024-07052-1","article-title":"Effectiveness of fracture liaison service in reducing the risk of secondary fragility fractures in adults aged 50 and older: A systematic review and meta-analysis","volume":"35","author":"Danazumi","year":"2024","journal-title":"Osteoporos. Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00198-021-05911-9","article-title":"The impact of fracture liaison services on subsequent fractures and mortality: A systematic literature review and meta-analysis","volume":"32","author":"Li","year":"2021","journal-title":"Osteoporos. Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40520-024-02761-3","article-title":"Secondary osteoporosis prevention: Three-year outcomes from a Fracture Liaison Service in elderly hip fracture patients","volume":"36","author":"Tamimi","year":"2024","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Migliorini, F., Giorgino, R., Hildebrand, F., Spiezia, F., Peretti, G.M., Alessandri-Bonetti, M., Eschweiler, J., and Maffulli, N. (2021). Fragility Fractures: Risk Factors and Management in the Elderly. Medicina, 57.","DOI":"10.3390\/medicina57101119"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/8755122520967632","article-title":"Romosozumab: A Novel Agent in the Treatment for Postmenopausal Osteoporosis","volume":"37","author":"Miller","year":"2021","journal-title":"J. Pharm. Technol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/ajhp\/zxaa285","article-title":"Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis","volume":"77","author":"Prather","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab Treatment in Postmenopausal Women with Osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.eprac.2023.06.011","article-title":"Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture Risk","volume":"29","author":"McClung","year":"2023","journal-title":"Endocr. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-021-06095-y","article-title":"A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis","volume":"33","author":"Singh","year":"2022","journal-title":"Osteoporos. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00198-024-07181-7","article-title":"Fracture liaison service\u2014A multidisciplinary approach to osteoporosis management","volume":"35","author":"Le","year":"2024","journal-title":"Osteoporos. Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-022-06600-x","article-title":"Fracture liaison service model: Project design and accreditation","volume":"34","author":"Tarantino","year":"2023","journal-title":"Osteoporos. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101780","DOI":"10.1016\/j.berh.2022.101780","article-title":"Osteoporosis and Fragility Fractures: Currently available pharmacological options and future directions","volume":"36","author":"Dimai","year":"2022","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/cpt.2709","article-title":"Medication Adherence Measurement Methods in Registration Trials Supporting the Approval of New Medicines: A Cross-Sectional Analysis of Centralized Procedures in the European Union 2010-2020","volume":"112","author":"Mantila","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.12.002","article-title":"Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe","volume":"122","author":"Siris","year":"2009","journal-title":"Am. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician\u2019s guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos. Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41573-023-00670-0","article-title":"Overcoming barriers to patient adherence: The case for developing innovative drug delivery systems","volume":"22","author":"Baryakova","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100217","DOI":"10.1016\/j.bonr.2019.100217","article-title":"The efficacy of osteoporotic treatment in patients with new spinal vertebral compression fracture pain, ADL, QOL, bone metabolism and fracture-healing\u2014In comparison with weekly teriparatide with bisphosphonate","volume":"11","author":"Shigenobu","year":"2019","journal-title":"Bone Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00198-007-0483-0","article-title":"The osteoporosis care gap in men with fragility fractures: The Canadian Multicentre Osteoporosis Study","volume":"19","author":"Papaioannou","year":"2008","journal-title":"Osteoporos. Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00002512-200724010-00003","article-title":"Patient adherence to osteoporosis medications: Problems, consequences and management strategies","volume":"24","author":"Papaioannou","year":"2007","journal-title":"Drugs Aging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s00198-015-3038-9","article-title":"Improving adherence to and persistence with oral therapy of osteoporosis","volume":"26","author":"Bianchi","year":"2015","journal-title":"Osteoporos. Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00774-019-01057-1","article-title":"Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: A post hoc analysis of the STRUCTURE trial","volume":"38","author":"Takada","year":"2020","journal-title":"J. Bone Miner. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"115574","DOI":"10.1016\/j.bone.2020.115574","article-title":"Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis","volume":"140","author":"Ebina","year":"2020","journal-title":"Bone"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100595","DOI":"10.1016\/j.tcr.2021.100595","article-title":"Successful treatment of humeral shaft nonunion with romosozumab: A case report","volume":"37","author":"Lee","year":"2022","journal-title":"Trauma. Case Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101077","DOI":"10.1016\/j.tcr.2024.101077","article-title":"Monoclonal antibody anti-sclerostin for treatment of pelvic insufficiency fractures in adult hypophosphatasia: A case report","volume":"53","author":"Schwab","year":"2024","journal-title":"Trauma. Case Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2106\/JBJS.19.00790","article-title":"A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures","volume":"102","author":"Schemitsch","year":"2020","journal-title":"J. Bone Jt. Surg."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/5\/148\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:30:48Z","timestamp":1760031048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/5\/148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,11]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["diseases13050148"],"URL":"https:\/\/doi.org\/10.3390\/diseases13050148","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,11]]}}}